Yes. Muse cells are a distinct, SSEA-3-positive subpopulation found within mesenchymal stromal cell (MSC) cultures and in mesenchymal tissues, not a separate, unrelated category. “MSC” describes the broader population; “Muse” identifies cells selected for additional properties, including stress tolerance and reported differentiation across all three germ layers. An ordinary MSC preparation is not automatically a selected Muse-cell product.Index
That biological distinction does not establish that Muse-cell treatment works better than MSC treatment. For a treatment decision, the relevant comparison is between defined products tested for the same condition, not between cell names.

What MSCs Are
MSCs are mesenchymal stromal cells, also often called mesenchymal stem cells. The classic International Society for Cellular Therapy criteria describe laboratory-grown human cells that adhere to plastic, express CD105, CD73, and CD90, lack specified blood-cell and immune markers, and differentiate into bone, fat, and cartilage cells under laboratory conditions. The negative-marker panel includes CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and HLA-DR.16923606
These are minimum identity criteria, not a guarantee of therapeutic potency. Two preparations meeting them need not be interchangeable: their tissue sources, isolation methods, and culture conditions must also be considered.16923606
MSCs should not be confused with blood-forming stem cells. The latter produce red cells, white cells, and platelets and are used in transplants to restore blood formation after certain cancer treatments. That established role does not establish the effectiveness of an MSC or Muse-cell infusion.Stem cell transplant
What Muse Cells Are
Muse stands for multilineage-differentiating stress-enduring. The original 2010 study identified these cells in human fibroblast and bone-marrow stromal cultures and directly in bone-marrow samples. Researchers isolated them using SSEA-3, a surface marker, together with the mesenchymal marker CD105.PMC2889306
Tohoku University’s laboratory outline describes Muse cells in bone marrow, skin, fat, and other mesenchymal tissues, including commercially available mesenchymal cultures. It reports approximately 1% in MSC transplants and 0.03% in marrow. Those are the laboratory’s descriptive estimates, not a guaranteed Muse-cell content for a particular clinic’s product.Index
In the original experiments, a single Muse cell could generate cells with characteristics of all three germ layers: ectoderm, mesoderm, and endoderm. That is broader than the bone-fat-cartilage differentiation required by the minimum MSC criteria. It does not mean the cells have been shown to rebuild any damaged human organ.PMC288930616923606
Muse Cells vs MSCs at a Glance
| Feature | Bulk MSC preparation | Selected Muse cells |
|---|---|---|
| Relationship | The broader, heterogeneous cell population | A subpopulation found within MSC cultures and mesenchymal tissues.Index |
| Identity testing | Classic MSC criteria include CD105, CD73, and CD90 positivity and a negative-marker panel | SSEA-3 selection, with CD105 used in the original tissue/culture isolation method.16923606PMC2889306 |
| Laboratory differentiation | Bone, fat, and cartilage under defined conditions | Reported single-cell differentiation into cells representing all three germ layers.16923606PMC2889306 |
| Meaning of the label | Does not specify a uniform product or prove clinical benefit | Requires evidence of selection and identity; broader laboratory behavior does not itself prove clinical benefit |
What the Experimental Differences Mean
Homing to Injured Tissue
Researchers have investigated whether Muse cells preferentially migrate to damaged tissue through sphingosine-1-phosphate (S1P) signaling and its receptor S1PR2. In a rabbit heart-attack model, approximately 14.5% of injected labeled Muse cells were estimated to have engrafted in the heart at three days. That is an animal engraftment estimate, not a human delivery rate or a treatment-success percentage.29475983
Tumor Findings and Safety
In the original study, Muse-enriched populations and cell clusters did not form teratomas in immunodeficient-mouse testes during observation for up to six months. This supports a specific experimental finding, not a claim that every Muse-cell preparation is tumor-free or safe for people.PMC2889306
When discussing cell collection, processing, infusion, and follow-up risks, ask for the exact product’s human safety data. Cell identity, manufacturing quality, and clinical safety are separate questions.
What Human Evidence Actually Shows
Regulatory approval applies to a named product and its authorized indication in a particular jurisdiction. The FDA’s approved-products list is not an approval of every treatment marketed under the same broad cell label.Approved cellular and gene therapy products
An FDA-Approved MSC Example
On December 18, 2024, the FDA approved remestemcel-L-rknd (Ryoncil), an allogeneic bone-marrow-derived MSC product, for steroid-refractory acute graft-versus-host disease in children aged two months and older. The FDA described it as the first FDA-approved MSC therapy. This is a specific United States approval, not a worldwide summary of MSC authorizations.Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric
The supporting multicenter, single-arm study included 54 children. Overall response at day 28 was 70% (95% confidence interval, 56.4% to 82.0%). The recommended initial course is 2 million cells per kilogram per intravenous infusion, twice weekly for four weeks, totaling eight infusions; further treatment depends on response. Common adverse reactions included infections, fever, and hemorrhage. These results do not establish benefit for arthritis, stroke, heart disease, or anti-aging.Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric
Early Muse-Cell Heart Research
A Japanese first-in-human study published in 2020 treated three patients with ST-elevation myocardial infarction after successful coronary intervention. All had left ventricular ejection fraction of 45% or less. Each received one intravenous dose of 15 million cells of CL2020, an investigational donor-derived Muse-cell product, with follow-up for 12 weeks. No adverse drug reaction was reported, and cardiac-function measurements improved. Without a control group, the study could not distinguish an effect of CL2020 from recovery after standard treatment; it also could not establish long-term safety.32522904
A Small Muse-Cell Stroke Trial
A Japanese single-center phase 2 trial published in 2023 randomized 25 patients to CL2020 and 10 to placebo, using double blinding. Patients had subacute ischemic stroke with modified Rankin Scale (mRS) scores of at least 3 at enrollment. They received one intravenous dose of 15 million cells or placebo 14 to 28 days after stroke onset, alongside standard rehabilitation. The protocol used no HLA matching or immunosuppressants; that does not establish that all donor-cell treatments can omit those precautions.PMC10925866
The primary endpoint was safety at 12 weeks, with follow-up continuing to 52 weeks. The key secondary efficacy endpoint was an mRS score of 2 or less at week 12: 10 of 25 patients (40.0%; 95% CI, 21.1% to 61.3%) in the CL2020 group versus 1 of 10 (10.0%; 95% CI, 0.3% to 44.5%) on placebo.PMC10925866
The CL2020 result exceeded the study’s prespecified registry-derived threshold of 8.7%, but that was not the same as demonstrating superiority over placebo. The estimated between-group response difference was 30 percentage points, with a 95% CI from −7.8 to 65.2 percentage points and a reported mid-P value of 0.080. The uncertainty therefore included no difference.PMC10925866
By week 12, adverse events occurred in 96% of the CL2020 group and 100% of the placebo group; adverse reactions were reported in 28% and 10%, respectively. One CL2020 recipient experienced Grade 4 status epilepticus, a serious seizure event whose relationship to treatment could not be ruled out. Larger studies are needed to clarify benefit and risk.PMC10925866
These two Muse studies are examples, not an exhaustive trial inventory. Neither compared Muse cells directly with a bulk MSC product. Comparing their results with a pediatric graft-versus-host disease study cannot tell you which cell type is better for a different disease.
What a Japanese Clinic Filing Means
A regenerative-medicine provision plan in Japan is not equivalent to product marketing approval or proof of efficacy. PMDA describes separate frameworks: the Act on the Safety of Regenerative Medicine covers research and medical practice, while the PMD Act regulates commercialization of regenerative medical products.0003
Likewise, trial registration establishes that a study was registered, not that treatment worked. A PubMed entry makes a publication discoverable; its design, controls, outcomes, and harms reporting still need examination.
Applying the Comparison to a Treatment Offer
Suppose a treatment brochure calls an infusion “Muse cells,” but the laboratory sheet reports only CD105, CD73, and CD90. Those results address part of the MSC identity panel; they do not document SSEA-3 selection or the Muse-cell proportion. Ask for the selection method and final-product identity, purity, viability, and release results before accepting the label. This is a document-checking scenario, not a patient case or a report of treatment experience.16923606PMC2889306
If the offer cites the stroke trial, compare the proposed product, diagnosis, treatment window, dose, and route with that protocol. A different preparation or use years after a stroke is not the intervention tested 14 to 28 days after onset.PMC10925866
- What tissue and donor source were used, and were Muse cells specifically selected?
- Which human study supports this exact product and use, including its control group, endpoints, follow-up, and adverse reactions?
- Is the offer an approved indication, participation in a clinical trial, or a private clinical service?
- What are the treatment steps, follow-up arrangements, costs, and alternatives?
The Bottom Line
Muse cells differ from bulk MSCs in selection markers and reported experimental behavior, while remaining related to the broader mesenchymal cell population. The distinction is biologically meaningful, but it does not establish clinical superiority. Judge an offer by its defined product, evidence for your condition, regulatory status, and risks, with help from your own medical team.
Need help organizing your questions?
Ask the support team what documentation is needed for a consultation. A qualified clinician should assess suitability; an inquiry does not establish eligibility or expected benefit.




